IFNG and ovarian cancer: Initial preclinical study conducted on an immunocompetent BRCA1-deficient BR5 murine ovarian cancer model revealed that anti-CTLA-4 combined with PARPi veliparib enhanced IFN-γ production and effector/memory T cell infiltration [146].